Core Viewpoint - Jinling Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Olaragolix tablets, marking a significant step in the development of a treatment for moderate to severe pain associated with endometriosis [1] Group 1 - Jinling Pharmaceutical's subsidiary, Jinling Pharmaceutical Factory, has been granted a Clinical Trial Approval Notice for Olaragolix tablets to conduct Phase III clinical research [1] - Olaragolix is an oral gonadotropin-releasing hormone (GnRH) antagonist primarily used for treating moderate to severe pain related to endometriosis [1] - Olaragolix tablets are included in the National List of Encouraged Generic Drugs, indicating potential market advantages [1]

证券代码： 000919 证券简称：金陵药业 公告编号：2025-065 金陵药业股份有限公司 关于分公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 金陵药业股份有限公司（以下简称"公司"）于 2025 年 6 月 24 日披露了《关于分公司收到噁拉戈利片受理通知书的公告》（公告编 号：2025-042），公司分公司金陵药业股份有限公司南京金陵制药厂 （以下简称"金陵制药厂"）收到国家药品监督管理局下发的噁拉戈 利片临床试验申请受理通知书。近日，金陵制药厂收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》，批准噁拉戈利片开 展Ⅲ期临床研究。现将相关情况公告如下： 一、《药物临床试验批准通知书》的主要内容 产品名称：噁拉戈利片 注册分类：化学药品 3 类 申请事项：临床试验申请 受理号：CYHL2500117、CYHL2500118 规格：150mg、200mg 申请的适应症：用于治疗与子宫内膜异位症相关的中度至重度疼 痛。 申请人：金陵药业股份有限公司南京金陵制药厂 审查结论：根据《中华人民共和国药品管理法》及有 ...

Core Viewpoint - Jinling Pharmaceutical has received approval for the Phase III clinical trial of Olaragolix, which is intended for the treatment of moderate to severe pain associated with endometriosis [1] Group 1: Company Developments - Jinling Pharmaceutical's subsidiary, Nanjing Jinling Pharmaceutical Factory, has been granted the clinical trial approval by the National Medical Products Administration [1] - Olaragolix is included in the National "Second Batch of Encouraged Generic Drug List" [1] Group 2: Industry Context - The pharmaceutical industry is characterized by high technology and high risk, with lengthy and complex processes from research and development to clinical trial approval and production [1] - The development of pharmaceutical products is susceptible to various uncertainties, which can impact the timeline and success of drug approval [1]

Group 1 - The company, Jinling Pharmaceutical, has acknowledged the impact of artificial intelligence applications on the pharmaceutical industry [1] - The company plans to research potential applications of artificial intelligence based on industry development and needs [1]

Core Insights - Jinling Pharmaceutical (000919.SZ) reported a total operating revenue of 1.601 billion yuan for the first half of 2025, ranking 32nd among disclosed peers, which represents a decrease of 113 million yuan or 6.62% year-on-year [1] - The net profit attributable to shareholders was 48.33 million yuan, ranking 65th among peers, down by 7.92 million yuan or 14.08% compared to the same period last year [1] - The net cash inflow from operating activities was 15.84 million yuan, ranking 91st among peers, a decrease of 5.52 million yuan or 25.82% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 20.34%, ranking 45th among peers, an increase of 0.79 percentage points from the previous quarter and 3.73 percentage points from the same period last year [3] - The latest gross profit margin is 19.43%, ranking 113th among peers, with a slight increase of 0.07 percentage points from the previous quarter but a decrease of 1.54 percentage points year-on-year [3] - The latest return on equity (ROE) is 1.28%, ranking 84th among peers, down by 0.09 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.08 yuan, ranking 77th among peers, a decrease of 0.02 yuan or 21.59% year-on-year [3] - The latest total asset turnover ratio is 0.26 times, ranking 35th among peers, a decrease of 0.02 times year-on-year [3] - The latest inventory turnover ratio is 5.02 times, ranking 1st among peers, an increase of 0.56 times or 12.49% year-on-year [3] Shareholder Structure - The number of shareholders is 35,400, with the top ten shareholders holding 322 million shares, accounting for 51.58% of the total share capital [3] - The largest shareholder is Nanjing New Industry Investment Group Co., Ltd., holding 41.59% of the shares [3]

Company Performance - Jinling Pharmaceutical reported a revenue of approximately 1.601 billion yuan for the first half of 2025, representing a year-on-year decrease of 6.62% [1] - The net profit attributable to shareholders of the listed company was approximately 48.33 million yuan, down 14.08% year-on-year [1] - The basic earnings per share were 0.0777 yuan, reflecting a year-on-year decline of 21.59% [1]

Group 1 - The core viewpoint of the article is that Jinling Pharmaceutical (000919.SZ) reported a decline in both revenue and net profit for the first half of 2025 compared to the same period last year [1] Group 2 - The company achieved operating revenue of 1.601 billion yuan, representing a year-on-year decrease of 6.62% [1] - The net profit attributable to shareholders of the listed company was 48.33 million yuan, down 14.08% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 35.51 million yuan, reflecting a year-on-year decline of 21.55% [1] - The basic earnings per share were reported at 0.0777 yuan [1]

金陵药业股份有限公司 二○二五年半年度财务报表附注 金陵药业股份有限公司 二○二五年半年度财务报表附注 （除特殊注明外，金额单位均为人民币元） 一、 公司基本情况 金陵药业股份有限公司（以下简称"公司"或"本公司"）是经中国人民解放军总后勤 部[1998]后生字第 261 号文批准,由南京金陵制药（集团）有限公司、南京军区福州总医院企 业管理局、南京军区后勤部苏州企业管理局、南京军区后勤部南京企业管理局一分局、南京 军区后勤部徐州企业管理局分别将其所属的南京金陵制药厂、福州梅峰制药厂、浙江天峰制 药厂、南京金威天然饮料公司、合肥利民制药厂以 1997 年 12 月 31 日为评估基准日经评估 确认后的净资产投入，采用发起设立方式成立的股份有限公司。1998 年 9 月 8 日，公司在 南京市工商行政管理局领取企业法人营业执照，注册号 24979447-5，注册资本人民币 20,000.00 万元。 经中国证券监督管理委员会证监发行字[1999]42 号文核准，公司于 1999 年 8 月 27 日在 深圳证券交易所采用"上网定价"发行方式，发行 8,000.00 万股人民币普通股,每股发行价 8.40 元，发 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：000919 证券简称：金陵药业 公告编号：2025-064 金陵药业股份有限公司 关于2025年半年度募集资金存放与使用情况的专项报告 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"） 《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》以及《深圳证券交易 所上市公司自律监管指南第 2 号——公告格式》的相关规定，金 陵药业股份有限公司（以下简称"公司"）就 2025年半年度募集 资金存放与使用情况作如下专项报告： 经中国证监会《关于同意金陵药业股份有限公司向特定对象发 行股票注册的批复》（证监许可〔2024〕41号）核准，公司向特定 对象发行人民币普通股（A 股） 117,924,528股，每股面值人民币 1.00 元 ， 每 股 发 行 价 格 为 人 民 币 6.36 元 ， 共 计 募 集 资 金 749,999,998.08元。本次发行涉及相关费用为7,367,708.75元（不 含税），实际募集资金净额为人民币74 ...

金陵药业股份有限公司 2025 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 非经营性 资金占用 资金占用方名称 占用方与上 市公司的关 联关系 上市公司核算的会计科目 2025 年期初占 用资金余额 2025 年度 1-6 月占用累计发 生金额（不含 利息） 2025 年度 1- 6 月占用资 金的利息 （如有） 2025 年度 1-6 月偿还累计发 生金额 2025 年度 6 月末占用资金 余额 占用 形成 原因 占用性质 控股股 东、实际 控制人及 其附属企 业 - - - - - 小计 - - - - - 前控股股 东、实际 控制人及 其附属企 业 - - - - - 小计 - - - - - 其他关联 方及其附 属企业 - - - - - 小计 - - - - - 总计 - - - - - 其他关联 资金往来 资金往来方名称 往来方与上 市公司的关 联关系 上市公司核算的会计科目 2025 年期初占 用资金余额 2025 年度 1-6 月占用累计发 生金额（不含 利息） 2025 年度 1- 6 月占用资 金的利息 （如有） 2025 年度 1-6 月偿还累计发 生金 ...